A carregar...
Traditional Approaches for Company Valuation Are Flawed for Valuing In Vivo Gene Therapy Companies
The era of gene therapy has begun. In recent years, potentially breakthrough datasets and rapidly expanding company pipelines have begun to overshadow the unfulfilled promise characteristic of the gene therapy sector in decades prior. One barometer for progress in the space can be seen in stock mark...
Na minha lista:
| Publicado no: | Hum Gene Ther Clin Dev |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Mary Ann Liebert, Inc., publishers
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6312046/ https://ncbi.nlm.nih.gov/pubmed/30547692 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/humc.2018.29037.gam |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|